Profile
Randall L.
Halcomb was the founder of Terns Pharmaceuticals, Inc. (founded in 2017) where he held the title of SVP-Chemistry & Early Development from 2017 to 2019.
He also held former positions as Director-Medicinal Chemistry at Gilead Sciences, Inc., Vice President-Chemistry at Igenica Biotherapeutics, Inc., and Vice President-Medicinal Chemistry at Pliant Therapeutics, Inc. (2016-2017).
Dr. Halcomb received a doctorate degree from Yale University and an undergraduate degree from The University of Alabama.
Former positions of Randall L. Halcomb
| Companies | Position | End |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Founder | 31/12/2018 |
| PLIANT THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/2016 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | - |
Training of Randall L. Halcomb
| Yale University | Doctorate Degree |
| The University of Alabama | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
- Stock Market
- Insiders
- Randall L. Halcomb
